This is a repository copy of *The role of osteopontin isoforms in cholangiocarcinoma*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/115540/

Version: Accepted Version

**Proceedings Paper:**

https://doi.org/10.1002/hep.28797

---

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
The role of osteopontin isoforms in cholangiocarcinoma

Marco A. Briones², Jason D. Coombes², Massimiliano Mellone⁴, R Rispoli⁵, Ezequiel Tolosa⁶, Paul P. Manka²,⁷, Naoto Kitamura², Alberto Quaglia¹⁰, Ali Canbay⁷, Gianfranco Alpini⁸,⁹, Shannon S. Glaser⁸,⁹, Roger Williams², Salvatore Papa²,¹¹, Martin E. Fernandez-Zapico⁶,¹², Wing-Kin Syn¹,³;

¹Medicine, Medical University of South Carolina, Charleston, SC; ²Division of Transplantation Immunology and Mucosal Biology, Faculty of Life Sciences and Medicine, Kings College London, The Institute of Hepatology, London, United Kingdom; ³Gastroenterology, Ralph H Johnson VAMC, Charleston, SC; ⁴Cancer Sciences Unit, University of Southampton, London, United Kingdom; ⁵Weatherall Institute of Molecular Medicine, John Radcliffe Hospital Oxford, Oxford, United Kingdom; ⁶Oncology, Mayo Clinic, Rochester, MN; ⁷Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany; ⁸Medicine, Central Texas Veterans Health Care System, Temple, TX; ⁹Medicine, Texas A&M Health Sciences Center, Temple, TX; ¹⁰Oncology, Mayo Clinic, Rochester, MN; ¹¹Liver Pathology, Kings College London, London, United Kingdom; ¹²Gastroenterology, Mayo Clinic, Rochester, MN

Introduction: Osteopontin (OPN) is upregulated in liver cancer. The OPN gene generates 3 isoforms (a, b and c) by alternative splicing. Each isoform induces a different cellular response during tumorigenesis. Studies of OPN isoforms in cholangiocarcinoma (CCA) have been limited to OPN-a (total OPN). We hypothesized that all OPN isoforms are overexpressed in CCA, and the pattern of isoform overexpression dictates CCA phenotype (i.e., more or less aggressive). Because both TGF-β and OPN are key regulators of cancer development and progression, we also evaluated the impact of OPN isoform expression on TGF-β signaling.

Methods: HuCCT1, SG231, and CCLP1, human CCA cell lines were used. Plasmids for each OPN isoform were used for overexpression. Expression for OPN-a, b, c, and epithelial-mesenchymal transition (EMT) markers (vimentin, aSMA, E-cadherin) were evaluated by qRT-PCR. Global gene expression changes were examined by microarray using SG231 cells. OPN isoform overexpression and their effects on the components of TGF-β pathway were evaluated by WB. Functional assays to evaluate cell motility and metalloprotease activity were performed, and the biological significance of OPN isoforms determined in a xenograft model. OPN isoform expression was also assessed in tumor and normal tissues obtained from patients undergoing liver resection for CCA.

Results: CCLP1 cells expressed the highest levels of total OPN and exhibited the most mesenchymal phenotype (high vimentin and low E-cadherin). In contrast, HuCCT1 expressed the lowest amount of OPN and exhibited an epithelial phenotype (high E-cadherin and low vimentin). In all 3 cell lines, OPN-a, and b mRNA were more abundant than OPN-c (~10 fold), and the forced overexpression of OPN-c resulted in the greatest increase in mesenchymal gene expression, enhanced Smad2/3 phosphorylation, and augmented metalloprotease activities, leading to increased cell migration. Microarray analysis confirmed that overexpression of OPN-c
induced the largest alteration in gene expression consistent with the mesenchymal phenotype, and the xenograft recapitulated in vitro findings, with higher tumour growth observed across all OPN isoforms compared with control, and highest growth rate detected in tumors expressing OPN-c In patients, the level of OPN isoform expression correlated with CCA grade

**Conclusions:** High levels of OPN were associated with a more aggressive CCA in mice and humans The specific over-expression of OPN-c directly promoted a more mesenchymal tumor phenotype, with enhanced migratory and metalloprotease activities, and increased Smad2/3 phosphorylation Future studies should evaluate utility of targeting OPN in CCA

Disclosures: The following people have nothing to disclose: Marco A Briones, Jason D Coombes, Massimiliano Mellone, R Rispoli, Ezequiel Tolosa, Paul P Manka, Naoto Kitamura, Alberto Quaglia, Ali Canbay, Gianfranco Alpini, Shannon S Glaser, Roger Williams, Salvatore Papa, Martin E Fernandez-Zapico, Wing-Kin Syn